Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK.

N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.

PMID:
30779531
2.

Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.

Segal NH, Ou SI, Balmanoukian A, Fury MG, Massarelli E, Brahmer JR, Weiss J, Schöffski P, Antonia SJ, Massard C, Zandberg DP, Khleif SN, Xiao F, Rebelatto MC, Steele KE, Robbins PB, Angra N, Song X, Abdullah S, Butler M.

Eur J Cancer. 2019 Mar;109:154-161. doi: 10.1016/j.ejca.2018.12.029. Epub 2019 Feb 4.

PMID:
30731276
3.

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.

Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI.

Lancet Oncol. 2018 Apr;19(4):451-460. doi: 10.1016/S1470-2045(18)30107-4. Epub 2018 Mar 9.

PMID:
29530667
4.

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.

Arbour KC, Naidoo J, Steele KE, Ni A, Moreira AL, Rekhtman N, Robbins PB, Karakunnel J, Rimner A, Huang J, Riely GJ, Hellmann MD.

PLoS One. 2017 Aug 3;12(8):e0182665. doi: 10.1371/journal.pone.0182665. eCollection 2017.

5.

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.

Masucci GV, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, Dobbin KK, Alvarez J, Robbins PB, Selvan SR, Streicher HZ, Butterfield LH, Thurin M.

J Immunother Cancer. 2016 Nov 15;4:76. eCollection 2016. Review.

6.

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.

Dobbin KK, Cesano A, Alvarez J, Hawtin R, Janetzki S, Kirsch I, Masucci GV, Robbins PB, Selvan SR, Streicher HZ, Zhang J, Butterfield LH, Thurin M.

J Immunother Cancer. 2016 Nov 15;4:77. doi: 10.1186/s40425-016-0179-0. eCollection 2016. Review.

7.

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.

Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, Jin X, Steele KE, Robbins PB, Blake-Haskins JA, Walker J.

Diagn Pathol. 2016 Oct 8;11(1):95.

8.
9.

Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.

Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA.

Nat Genet. 2005 Jul;37(7):745-9. Epub 2005 Jun 12.

10.

Peptide delivery to tissues via reversibly linked protein transduction sequences.

Robbins PB, Oliver SF, Sheu SM, Goodnough JB, Wender P, Khavari PA.

Biotechniques. 2002 Jul;33(1):190-2, 194.

11.

Sustainable systemic delivery via a single injection of lentivirus into human skin tissue.

Baek SC, Lin Q, Robbins PB, Fan H, Khavari PA.

Hum Gene Ther. 2001 Aug 10;12(12):1551-8.

PMID:
11506697
12.

Impact of laminin 5 beta3 gene versus protein replacement on gene expression patterns in junctional epidermolysis bullosa.

Robbins PB, Sheu SM, Goodnough JB, Khavari PA.

Hum Gene Ther. 2001 Jul 20;12(11):1443-8.

PMID:
11485635
13.

In vivo restoration of laminin 5 beta 3 expression and function in junctional epidermolysis bullosa.

Robbins PB, Lin Q, Goodnough JB, Tian H, Chen X, Khavari PA.

Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5193-8. Epub 2001 Apr 10.

14.
15.

High-resolution analysis of cytosine methylation in the 5ĺong terminal repeat of retroviral vectors.

Wang L, Robbins PB, Carbonaro DA, Kohn DB.

Hum Gene Ther. 1998 Nov 1;9(16):2321-30.

PMID:
9829531
16.

Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells.

Robbins PB, Skelton DC, Yu XJ, Halene S, Leonard EH, Kohn DB.

Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10182-7.

17.

Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells.

Robbins PB, Yu XJ, Skelton DM, Pepper KA, Wasserman RM, Zhu L, Kohn DB.

J Virol. 1997 Dec;71(12):9466-74.

18.

The HIV-1 gp120 envelope protein has the intrinsic capacity to stimulate monokine secretion.

Clouse KA, Cosentino LM, Weih KA, Pyle SW, Robbins PB, Hochstein HD, Natarajan V, Farrar WL.

J Immunol. 1991 Nov 1;147(9):2892-901.

PMID:
1918997
19.

Viral antigen stimulation of the production of human monokines capable of regulating HIV1 expression.

Clouse KA, Robbins PB, Fernie B, Ostrove JM, Fauci AS.

J Immunol. 1989 Jul 15;143(2):470-5.

PMID:
2544645

Supplemental Content

Loading ...
Support Center